Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAFT
2025-523465-21-00Phase 3Authorised
- Sponsor
- Region Stockholm
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of rituximab in fibromyalgia (FM), sponsored by Region Stockholm. Planned start Feb 2026; status: authorised.
02
Drugs
rituximab
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on 2025-523465-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523465-21-00.